Ligand Pharma (LGND) Tops Q4 EPS by 39c ; Offers Guidance

Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.05, $0.39 better than the analyst estimate of $0.66. Revenue for the quarter came in at $28.1 million versus the consensus estimate of $25.65 million.

GUIDANCE:

Ligand Pharma sees FY2024 EPS of $4.25-$4.75, versus the consensus of $4.28. Ligand Pharma sees FY2024 revenue of $130-142 million, versus the consensus of $137.7 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND)
• Morgan Stanley Upgrades Dexerials Corp (4980:JP) to Overweight